Therefore, targeting CXCR4 and FAK could be a way to overcome DOX resistance and enhance the anti-invasive effects of CXCR4 and FAK inhibitors in NSCLC cells. This evidence concerns the gene PTK2 and non-small cell lung carcinoma.